Research and Development and Sales Competition Among Companies
First written in FY2016. 9 of 14 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 31 of 90 companies on the "Worse" side.
- FY2025MitigatedAnnual report
「The company has also established investment recovery criteria and evaluates and manages progress through management meetings, the Board of Directors and other bodies.」
In response to the risks of delays in R&D, difficulty recovering investments and misalignment with market trends, the company added the establishment of investment recovery criteria and evaluation and management by management meetings and the Board of Directors. - FY2022MitigatedAnnual report
「In light of these risks, the Group formulates business strategies aligned with changes in the business environment under the EIKEN ROAD MAP 2030 and the medium-term management plan, promotes new products and technologies strategically, and manages R&D progress through management meetings, the Board of Directors and other bodies.」
In response to the risks of delays or interruptions in R&D and declining competitiveness due to competitors' technologies, the company describes the formulation of business strategies, the promotion of new products and technologies, and progress management by management meetings and the Board of Directors. - FY2021ReframedAnnual report
「At the same time, the clinical diagnostics industry faces intense development competition driven by technological innovation. Delays or interruptions in research and development could make it difficult to recover research and development investment and may affect the group's financial position and operating results. In addition, if competitors' innovative technologies reduce the competitiveness of the company's products, product sales may decline.」
The conventional risk of competition in research and development and sales is described more specifically as the difficulty of recovering R&D investments, declining product competitiveness due to competitors' innovative technologies, and lower sales. - FY2019-Q3RestatedAnnual report
「During the nine-month cumulative consolidated period under review, there were no new business or other risks, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition among companies. - FY2019-Q2RestatedAnnual report
「During the six-month period ended the second quarter of the current consolidated fiscal year, there were no new business risks or material changes to the business risks described in the previous fiscal year's Annual Securities Report.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition among companies. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition among companies. - FY2018RestatedAnnual report
「The group works to conduct research and development rapidly and efficiently and develops new products and improves existing products. However, the clinical diagnostics industry faces intense development competition driven by technological innovation, and delays or interruptions in research and development may affect the group's financial position and operating results.」
The company continues to disclose the risk of research and development and sales competition, together with the possibility of an impact from delays or interruptions in research and development. - FY2018-Q3RestatedAnnual report
「During the nine-month cumulative consolidated period under review, there were no new business or other risks, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition among companies. - FY2018-Q2RestatedAnnual report
「During the six-month period ended the second quarter of the current consolidated fiscal year, there were no new business risks or material changes to the business risks described in the previous fiscal year's Annual Securities Report.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition. - FY2017RestatedAnnual report
「The group works to conduct research and development rapidly and efficiently and develops new products and improves existing products. However, the clinical diagnostics industry faces intense development competition driven by technological innovation, and ongoing research and development and sales competition with other companies' products. Depending on the outcome of this competition, the group's financial position and operating results may be affected.」
The company continues to disclose the risk of research and development and sales competition. - FY2017-Q3RestatedAnnual report
「During the nine-month cumulative consolidated period under review, there were no new business or other risks, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition. - FY2017-Q2RestatedAnnual report
「During the six-month period ended the second quarter of the current consolidated fiscal year, there were no new business risks or material changes to the business risks described in the previous fiscal year's Annual Securities Report.」
The company has determined that there have been no new risks or significant changes concerning research and development and sales competition. - FY2017-Q1MaterialisedAnnual report
「Sales of biochemical test reagents were ¥162 million, down 5.1% year on year, due mainly to price competition and other factors.」
Regarding the risk of competition among companies, price competition has materialized as a decline in sales of biochemical test reagents. - FY2016First statedAnnual report
「The clinical diagnostics industry faces intense development competition driven by technological innovation, and ongoing research and development and sales competition with other companies' products.」
The company indicates that the outcome of competition could affect its financial position and operating results.